Chandra Bhagat Pharma Ltd (CBPL) — shareholding pattern, promoter holding, financials and share price
About Chandra Bhagat Pharma Ltd (CBPL)
Chandra Bhagat Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as CBPL and on the BSE under scrip code 542934. Its ISIN is INE07QQ01016.
Incorporated in 2003, Chandra Bhagat Pharma Ltd manufactures chemical and pharmaceutical products. [1]
Chandra Bhagat Pharma Limited focuses on marketing critical care and pharmaceutical products. It initially began as a private company in 2003, later becoming public in 2019.
The company markets a diverse range of pharmaceutical formulations across major therapeutic categories, such as oncology, cardiology, and antibiotics.
Listed peers in Pharmaceuticals: Walpar Nutritions Ltd, Welcure Drugs & Pharmaceuticals Ltd, Sunrest Lifescience Ltd, Medicamen Organics Ltd, Medistep Healthcare Ltd, Gujarat Terce Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹38.56 a share on 10 Jul 2026, Chandra Bhagat Pharma Ltd (CBPL) was valued at a price-to-earnings ratio of 9.54x against an industry P/E of 36.41x and a price-to-book of 0.88x on a book value of ₹43.9 per share. Solomo computes return on equity of 9.2% and return on capital employed of 12.3% from filed results.
- P/E
- 9.54x
- Industry P/E
- 36.41x
- P/B
- 0.88x
- EPS (TTM)
- ₹4.04
- Book value / share
- ₹43.9
- ROE
- 9.2%
- ROCE
- 12.3%
- ROA
- 3.24%
- Debt / equity
- 0.5x
- Dividend yield
- 0%
- EBITDA margin
- 6.2%
- 52-week range
- ₹29.7 – ₹59
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Chandra Bhagat Pharma Ltd (CBPL) reported revenue of ₹116 crore, net profit of ₹3 crore and earnings per share of ₹4.04. That compares with revenue of ₹87 crore and net profit of ₹1 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹91 crore and net profit ₹3 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 94 | 120 | 221 | 87 | 116 |
| Net profit (₹ cr) | 1 | 1 | 2 | 1 | 3 |
| EPS (₹) | 1.06 | 1.21 | 2.03 | 1.14 | 4.04 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | -1.60% | -2.68% | -60.83% |
| Profit growth | 22.20% | 2.49% | -43.79% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 73.02% of Chandra Bhagat Pharma Ltd (CBPL). Market capitalisation was ₹29 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2020.
Largest disclosed public shareholders in Mar 2026: Team Anamika Algo Limited 7.94%, HUF 2.28%, Prashant A Thakkar Huf 1.64%, Riddhi Abhinav Chheda 1.56%, Multiply Finvest Private Limited 1.14%, First Rate Investments Private Limited 1.13%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 73.02% | - | - | - | 26.98% |
| Sep 2025 | 72.19% | - | 0.61% | - | 27.81% |
| Mar 2025 | 71.2% | - | 0.61% | - | 28.8% |
| Sep 2024 | 69.29% | - | 0.48% | - | 30.71% |
| Mar 2024 | 68.77% | - | 1.33% | 0.89% | 31.23% |
| Sep 2023 | 68.69% | - | 1.33% | 0.89% | 31.31% |
| Mar 2023 | 68.24% | - | 0.85% | - | 31.76% |
| Sep 2022 | 69.09% | - | 0.85% | - | 30.91% |